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Oxidized LDL Regulates Macrophage Gene
Expression through Ligand Activation of PPARg
so-called scavenger receptors, it must first undergo
chemical or enzymatic modification. There is now con-
siderable evidence to suggest that it is oxidative modifi-
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cation of the LDL particle that is of primary importance*The Salk Institute of Biological Studies
for macrophage uptake of LDL in vivo (Steinberg, 1997,²Howard Hughes Medical Institute
and references therein). Each of the three major compo-La Jolla, California 92037
nents of the arterial wall, endothelial cells, smooth mus-³Department of Pathology
cle cells, and macrophages, are capable of oxidativelyUniversity of California
modifying LDL to a form that can be recognized bySan Diego, California 92093
macrophage scavenger receptors (Steinberg, 1997). A
number of mechanisms have beenpostulated to contrib-
ute to cell-mediated oxidation of LDL, including the ac-
tion of lipoxygenases and the generation of superoxideSummary
anion (Steinbrecher et al., 1984; Kuhn et al., 1994; Folcik
et al., 1995). The demonstration that anti-oxLDL autoan-Macrophage uptake of oxidized low-density lipoprotein
tibodies can be detected in human serum, the presence(oxLDL) is thought to play a central role in foam cell
of oxidized fatty acids and cholesterol metabolites information and the pathogenesis of atherosclerosis.
atherosclerotic lesions, and the observation that antioxi-We demonstrate here that oxLDL activates PPARg-
dant drugs can slow the progression of atherosclerosisdependent transcription through a novel signaling
in experimental animal models all support a central rolepathway involving scavenger receptor-mediated parti-
for oxLDL in the pathogenesis of atherosclerosis.cle uptake. Moreover, we identify two of the major
The LDL particle acquires a number of important bio-oxidized lipid components of oxLDL, 9-HODE and 13-
logical activities as a result of oxidative modification inHODE, as endogenous activators and ligands of PPARg.
addition to the ability to bind scavenger receptors.Our data suggest that the biologic effects of oxLDL
OxLDL is both a potent chemoattractant for circulatingare coordinated by two sets of receptors, one on the
monocytes and a potent inhibitor of resident macro-cell surface, which binds and internalizes the particle,
phage motility (Quinn et al., 1987). These properties mayand one in the nucleus, which is transcriptionally acti-
help to explain how monocytes are recruited to and
vated by its component lipids. These results suggest
trapped within the early atherosclerotic lesion. OxLDL
that PPARg may be a key regulator of foam cell gene has also been shown to be a powerful regulator of mac-
expression. rophage gene expression. A number of genes involved
in the inflammatory response, including those encoding
TNFa, IL-1a, IL-1b, IL-6, and PDGF, are known to beIntroduction
modulated by exposure to oxLDL (Hamilton et al., 1990;
Fong et al., 1991; Malden et al., 1991). Moreover, experi-Atherosclerosis is responsible for more than half of all
ments in cultured systems have suggested that oxLDLmortality in developed countries. The formation of the
is able to stimulate its own uptake, presumably throughatherosclerotic lesion is a complex process involving the
induction of one or more scavenger receptors (Han et
injured endothelium, monocytes/macrophages, smooth
al., 1997). The mechanisms by which oxLDL exerts these
muscle cells, and a regulatory network of growth factors
diverse effects have not been defined.
and cytokines (reviewed in Ross, 1993). The earliest The nuclear hormone receptors comprise a family of
macroscopically recognizable lesion of atherosclerosis transcription factors that regulates differentiation and
is the fatty streak, an aggregation of cholesterol-laden cell and tissue homeostasis (Evans, 1988). The tran-
macrophages known as foam cells within the artery wall. scriptional activityof thesereceptors is tightly controlled
Although the sequence of morphological changes that by small lipophilic molecules that serve as ligands. The
characterize the atherogenic process is well established production, availability, and metabolic stability of these
(Bujaet al., 1983), thebiochemical signals and regulatory molecules represents an important control point in the
circuits that underlie the differentiation of foam cells processes regulated by their receptors. Peroxisome
within atherosclerotic lesions remain poorly understood. proliferator activated receptor g (PPARg) is a nuclear
There is a strong positive correlation between high- receptor that has been linked to adipocyte differentia-
plasma low-density lipoprotein (LDL) levels and the de- tion and the control of cellular lipid uptake (Chawla et
velopment of atherosclerosis. The pioneering work of al., 1994; Tontonoz et al., 1994b). PPARg forms a hetero-
Brown and Goldstein established that the principal path- dimeric DNA binding complex with the 9-cis retinoic
way for macrophage uptake of LDL involves a group of acid receptor (RXR; Kliewer et al., 1992) and serves as a
receptors distinct from the LDL receptor (Goldstein et transcriptional regulator of genes involved in adipocyte
al., 1979). In order for LDL to be recognized by these lipid metabolism (Tontonoz et al., 1994a). We have re-
cently found that the PPARg:RXR heterodimer can regu-
late monocyte gene expression and differentiation and
is expressed at high levels in the foam cells of athero-§To whom correspondence should be addressed.
‖ These authors contributed equally to this work. sclerotic lesions (Tontonoz et al., 1998, this issue of Cell).
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These observations suggest that endogenous PPARg
activators may function as important regulators of mono-
cytic gene expression and may be present at high levels
at sites of atherogenesis.
The similarities between the biologic consequences
of oxLDL exposure and the effects of ligand activation of
PPARg:RXR heterodimers in myelomonocytic cell lines
suggested the possibility that the oxLDL particle itself
may be a source of endogenous PPARg ligand. We dem-
onstrate here that oxLDL can regulate PPARg-depen-
dent transcription following scavenger receptor-medi-
ated cellular uptake. Moreover, we identify two of the
major oxidized lipid components of oxLDL, 9-HODE and
13-HODE, as endogenous activators and ligands of
PPARg. These results establish a novel molecular mech-
anism linking oxLDL to the transcriptional control of
macrophage gene expression and suggest an unex-
pected role for PPARg in thepathogenesis of atheroscle-
rosis.
Results
OxLDL and PPARg Ligands Trigger
Monocyte Maturation
Human peripheral blood monocyte cultures and the hu-
Figure 1. OxLDL and PPARg Ligands Induce CD14 Expression and
man monocytic cell line THP-1 were used as model OxLDL Association in Human Monocytes and THP-1 Cells
systems to compare the ability of oxLDL and PPARg Human peripheral monocytes (A) and THP-1 cells (B) were treated
ligands to promote monocytic differentiation. Cells were with the indicated combinations of 3 mM 15d-PG-J2, 100 nM LG268,
cultured for 4 days in the presence of 5 mM of the PPARg 150 mg protein/ml LDL, or oxLDL. CD14 expression levels were
determined by flow cytometry. Mean fluorescence intensities of theligand 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2), or
counted populations are presented. (C) Following 4 days of culture150 mg protein/ml LDL or oxLDL, either alone or in com-
in the absence or presence of 100 nM LG268 and 100 mg protein/bination with 100 nM of the RXR-selective ligand LG268
ml lipoproteins, THP-1 cells were washed, replated, and incubated(Boehm et al., 1995). Induction of the differentiation-
with DiI-labeled oxLDL. Cell-associated fluorescence was quanti-
linked surface antigen CD14 was analyzed by flow cy- tated by flow cytometry. The data are presented as increase in
tometry. As shown in Figure 1A, both 15d-PGJ2 and specific oxLDL association. In these experiments, the fluorescence
oxLDL induced expression of CD14 on human mono- of the oxLDL 1 LG268±treated culture represents a 5-fold increase
over background. The experiments were repeated three times withcytes (approximately 3-fold), while LDL did not. Surpris-
similar results.ingly, the activity of both 15d-PGJ2 and oxLDL was
enhanced by addition of LG268. The combination of
oxLDL and LG268 also led to an induction of CD14
uptake observed in THP-1 cells. The two scavenger re-expression in THP-1 cells (Figure 1B). These cells were
ceptors most clearly linked to oxLDL uptake in vivo aregenerally less responsive than human peripheral blood
SR-A (Matsumoto et al., 1990; Suzuki et al., 1997) andmonocytes, and combined treatment of PPARg-activa-
CD36 (Endemann et al., 1993; Nozaki et al., 1995; Huhtors or oxLDL and LG268 was employed to induce maxi-
et al., 1996). We performed Northern analysis of totalmal response.
cellular RNA from THP-1 cells to determine whetherWe nextexplored the ability of oxLDL and RXR ligands
expression of mRNA encoding either CD36 or SR-A typeto regulate macrophage uptake of oxLDL in vitro. THP-1
I/II was regulated by exposure to oxLDL. As shown incells were preincubated for 4 days with 100 mg/ml native
Figure 2A, while unstimulated THP-1 cells expressedor oxidized LDL in the presence or absence of LG268.
little detectable mRNA for either SR-A or CD36, stimula-The cells were then washed, replated, and incubated
tion with the combination of oxLDL and LG268 resultedfor 4 hr in the presence of 20 mg/ml DiI-labeled oxLDL
in a marked up-regulation of SR-A type I mRNA andand the cell-associated fluorescence quantitated by
multiple splicing variants of CD36 mRNA. A smaller in-flow cytometry. As shown in Figure 1C, both LG268
duction of CD36 and SR-A expression was observedand oxLDL induced a similar small increase in label
when cells were treated with oxLDL alone (data notassociation. The combination of the two, however, re-
shown).sulted in a synergistic increase, approximately 4-fold
The expression of CD36 on the surface of oxLDL-greater than that seen with either treatment alone. As
treated human peripheral blood monocytes and THP-1expected, LDL failed to stimulate uptake of oxLDL, and
cells was examined by flow cytometry using a mono-the combination of LDL and LG268 was not different
clonal antibody to CD36. A shown in Figure 2B, thefrom LG268 alone.
amount of immunoreactive CD36 on human monocytes
was significantly increased when cells were treated withOxLDL Induces Expression of Scavenger
the combination of 50 mg/ml oxLDL and LG268 or 15d-Receptors SR-A and SR-B (CD36)
PGJ2 and LG268. Similarly, in THP-1 cells, a strongWe next endeavored to determine which cell surface
receptor(s) were associated with the inducible oxLDL induction of surface CD36 expression was observed
Components of Oxidized LDL Are PPARg Ligands
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Figure 2. OxLDL Induces Expression of the
Scavenger Receptors CD36 and SR-A
(A) Northern analysis of CD36 and SR-A ex-
pression in THP-1 cells. Cells were treated
with the indicated lipoproteins (100 mg pro-
tein/ml) and 100 nM LG268 for 4 days. Total
cellular RNA was prepared and analyzed by
Northern blotting. Expression of CD36 on
human monocytes (B) and THP-1 cells (C)
upon treatment with oxLDL and agonists of
PPARg:RXRa heterodimers (3mM 15d-PGJ2
or 15mM troglitazone [TRO] and 100 nM
LG268). Expression of CD36 was determined
by flow cytometry using an anti-human CD36
antibody. Mean fluorescence intensity (B) or
fluorescence distribution of the counted cell
population (C) is presented from a represen-
tative experiment. Each experiment was re-
peated at least three times with similar re-
sults.
following treatment with the combination of oxLDL and LG268 would potentiate the transcriptional activity in-
duced by oxLDL. Figure 3B shows that the addition ofLG268, as well as with the combination of LG268 and a
100 nM LG268 to increasing doses of oxLDL resultedPPARg-specific ligand (troglitazone [TRO] or 15d-PGJ2;
in a synergistic activation of the reporter gene. The dif-Figure 2C). Consistent with theNorthern analysis (Figure
ference between control and simultaneous treatment2A), an induction of surface SR-A expression was de-
with 50 mg protein/ml oxLDL and LG268 is more thantected following treatment with oxLDL but not with
30-fold. While these data indicated that oxLDL can influ-PPARg-specific ligands (Tontonoz et al., 1998, and data
ence the transcriptional activity of the PPARg:RXR het-not shown).
erodimer, it was not clear whether this effect reflected
ligand-dependent or ligand-independent activation.
The Oxidized LDL Particle Stimulates If a ligand is involved in the activation of the receptor,
PPARg-Dependent Transcription then the ligand-binding domain (LBD) of PPARg should
The ability of both PPARg ligands and oxLDL to syner- be sufficient for transactivation. We therefore employed
gize with LG268 in the induction of CD14 and CD36 a chimeric receptor/reporter system in which the ligand-
expression suggested that some of the biologic effects binding domain of mPPARg is fused to the DNA-binding
of oxLDL might be mediated by transcriptional events domain of the yeast transcription factor Gal4. The chi-
involving the PPARg:RXR heterodimer. To explore this meric receptor is able to bind to the Gal4 DNA binding
possibility, we assayed the ability of native and oxidized motif but activates transcription only in response to li-
lipoproteins to modulate the activity of PPARg in tran- gands bound to the LBD of PPARg (Forman et al., 1995).
sient transfection systems. A PPARE (peroxisome prolif- This assay system is independent of endogenous PPAR
erator activated receptor response element)± containing and RXR and is a sensitive and specific reporterof ligand
reporter gene was transfected into CV-1 cells along with binding the PPARg LBD. Figure 3C demonstrates that
CMX-hPPARg and CMX-hRXRa expression vectors in the transcriptional activity induced by exposure to oxLDL
the presence of either native or oxidized LDL. Native depends on the presence of both the GAL4 response
LDL had no influence on reporter activity, even at high element (UAS) and the PPARg LBD. This effect is clearly
concentrations (50±150 mg/ml; Figure 3A and data not dose-dependent, resulting in a greater than 10-fold in-
shown). Surprisingly, however, oxLDL stimulated re- crease in reporter activity at doses of 150 protein mg/
porter activity in a dose-dependent manner at concen- ml of oxLDL. Reporter activity was further stimulated
trations as low as 10 mg/ml, indicating that oxLDL was by addition of the RXR-specific ligand LG268 in the
activating PPARg-mediated transcription. presence of cotransfected RXR-LBD (data not shown).
The activityof thePPARg:RXR heterodimer is maximal We also explored whether there was any correlation
when both receptors are bound by their respective li- between the length of time the LDL particle was sub-
jected to oxidative conditions and the ability to inducegands (Kliewer et al., 1992). We therefore tested whether
Cell
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Figure 3. OxLDL Activates PPARg-Depen-
dent Transcription in CV-1 Cells
CV-1 cells were transiently transfected with a
PPAR-reporter gene and expression vectors
for PPARg and RXRa. The indicated amount
of lipoproteins alone (A) or in combination
with 100 nM LG268 (B) were added to the
transfected cells and normalized reporter
activity was determined. (C) Reporter gene
induction by oxLDL requires DNA-bound
PPARg-LBD. CV-1 cells were transiently trans-
fected with a reporter gene containing four
copies of a Gal4 binding site (UAS-TK-luc 5
MH-100-TK-luc) in the presence or absence
of a chimeric receptor (Gal-mPPARg-LBD).
OxLDL was added to the transfected cells
and normalized reporter activity was deter-
mined. A TK-luc reporter gene lacking PPAR
or Gal4 binding sites was used as a negative
control. (D) The activity of partially oxidized
LDL (50 mg protein/ml) was determined using
the transient transfection system described
in (C) and LDL oxidized in vitro for 0.5, 1, 2,
4, 8, 16, or 24 hr. The means of three indepen-
dent determinations 6 SD are shown.
transcription of the reporter gene. Figure 3D compares et al., 1989) induced a 3-fold activation. Remarkably,
two oxidized metabolites of linoleic acid, 9-hydroxyoc-the activity of LDL oxidized for various lengths of time
(from 0.5 to 24 hr) in the transient transfection assay. tadecadienoic acid (9-HODE) and 13-hydroxyoctadeca-
From this experiment, it is clear that the longer the oxida- dienoic acid (13-HODE) were potent activators (Figure
tion period, the greater the transcriptional response. 4A). At a concentration of 20 mg/ml, these compounds
Thus, the differential ability of LDL and oxLDLto activate induced 12- and 7.5-fold inductions of the reporter gene,
PPARg is directly related to the oxidation state of the respectively. 9-HODE cholesteryl ester was inactive, in-
particle. dicating that cleavage of the ester bond is critical for
transport and/or receptor activation. The end product
Oxidized Linoleic Acid Activates PPARg of oxidized fatty acid metabolism, 4-OH nonenal, was
The oxidation of LDL is a complex process involving also inactive.
both the protein and the lipid moieties of the particle The oxidation of linoleic acid in vivo is mediated by 15-
(reviewed in Steinberg, 1997). Each of the lipid compo- lipoxygenase and free oxygen radicals, resulting in hy-
nents can undergo oxidation, including sterols, phos- droperoxy, hydroxy, and oxo metabolites (Steinbrecher
pholipids, cholesterol esters, and triglycerides. Since et al., 1984; Kuhnet al., 1994; Folcik etal., 1995). Interest-
certain fatty acid derivatives such as prostaglandin J2 ingly, the activity of these structural and metabolic iso-
have been shown to serve as ligands for PPARg (Forman mers in the transfection assay were remarkably similar.
et al., 1995; Kliewer et al., 1995, 1997), we hypothesized The (S) stereoisoform of both 9- and 13-HODE were
that oxidation of one or more of the lipid components slightly more potent than the (R) stereoisoforms, and
of oxLDL might result in the formation of an effective the oxo metabolites were slightly more potent than the
PPARg activator. To test this hypothesis, we conducted hydroxy ones (Figure 4B). To determine the concentra-
a screen of oxidized sterols and fatty acids that are tion required for PPARg activation, a dose response
known to be present in the oxLDL particle. Again, we curve was constructed for 9(S)-HODE and 13(S)-HODE.
utilized a transient transfection assay that combines a As shown in Figure 4C, 9(S)-HODE was more potent
chimeric Gal4-PPARg LBD receptor and a UAS-con- than 13(S)-HODE, and both compounds exhibited dose-
taining reporter gene. Following transfection, CV-1 cells dependent activation of the reporter in the range of 2.5
were treated for 24 hr with 20±40 mg/ml of the indicated mM±60 mM.
compounds (Figure 4A). Neither cholesterol nor anyof its
oxidized metabolites we tested induced transcriptional
9-HODE and 13-HODE Induce Monocyteactivity in this assay. Among the free fatty acids tested,
Maturation and Induce Scavengeroleic acid, erucic acid, and linoleic acid were inactive;
Receptor Expressionlinolenic acid and arachidonic acid showed minimal ac-
The above data indicated that linoleic acid metabolitestivity (1.5- to 3-fold induction of the reporter gene). The
15-OH metabolite of arachidonic acid (15-HETE; Simon oxidized at the 9 or 13 positions can serve as novel
Components of Oxidized LDL Are PPARg Ligands
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Figure 4. Oxidized Linoleic Acid Metabolites (9-HODE and 13-HODE) Activate PPARg-Dependent Transcription
(A) CV-1 cells were transiently transfected with Gal-mPPARg-LBD and a reporter gene containing Gal4 binding sites. The listed compounds
were dissolved in ethanol and added to the transfected cells at a final concentration of 20 mg/ml, except for 9-HODE cholesteryl ester, which
was added at 40 mg/ml. Reporter gene activity was determined and is presented as fold induction over solvent (ethanol) control. The structures
of linoleic acid, 9-HODE, 13-HODE, and 4-OH nonenal are shown in the upper part of the panel.
(B) The relative activities of linoleic acid metabolites oxidized at the 9- or 13 position were compared. The activity of each compound at a
concentration of 20 mg/ml is presented as a percentage of 9(S)-HODE activity (asterisk).
(C) Dose-response curves for activation of PPARg by 9(S)-HODE and 13(S)-HODE.
The means 6SD of three independent determinations are presented.
PPARg activators. We then asked whether these com- possibility, we established a ligand displacement assay
using a baculovirus-expressed full-length mouse PPARgpounds alone could recapitulate some of the biologic ac-
tivities of the intact oxLDL particle. The ability of 9-HODE 1-GST fusion protein immobilized on glutathione-Seph-
and 13-HODE to induce differentiation-linked surface arose beads and [3H]- BRL49653, a high-affinity thiazoli-
marker expression in human peripheral blood mono- dinedione ligand of PPARg (Forman et al., 1995; Leh-
cytes and THP-1 cells was analyzed by flow cytometry mann et al., 1995). The ability of known PPARg ligands
(Figure 5). Treatment of cells for 4 days with 15 mg/ and oxidized fatty acids to compete for [3H]-BRL49653
ml 9-HODE increased CD14 expression levels on both binding was determined using this assay. As expected
human monocytes and THP-1 cells (Figures 5A and 5B). from previous work, BRL49653 and 15d-PGJ2 (10 mM)
Moreover, this activity was potentiated by simultaneous were effective competitors for [3H]-BRL49653 binding
treatment with theRXR-selective retinoid LG268. A simi- (Figure 6A). Interestingly, the oxidized metabolites of
lar inductionof CD36 expression was observed in THP-1 linoleic acid 9-HODE, 9-oxoODE, 13-HODE, and 13-
cells (Figure 5C). Again, both 9- and 13-HODE alone oxoODE (100 mM) were also effective competitors. Other
induced a significant increase in CD36 expression (note oxidized components of the oxLDL particle, such as
the shift of the fluorescence histogram), and simultane- 7-keto cholesterol, failed to compete (Figure 6A and
ous treatment with LG268 had a synergistic effect. Con- data not shown). Dose response competition curves
sistent with the transactivation studies (Figure 4), 9-HODE (Figure 6B) were constructed to compare the in vitro
was more potent than 13-HODE. In similar experiments, binding affinity of known synthetic and natural PPARg
no change in surface SR-A I/II expression was observed ligands with 9- and 13-HODE. The relative affinity of
(data not shown). Taken together, these results strongly these compounds for binding to PPARg correlates
suggest that oxLDL can regulate macrophage gene ex- well with their potency in transient transfection assays:
pression by providing the cell with endogenous activa- BRL49653 . 15d-PGJ2 . 9-HODE . 13-HODE. While
tors of PPARg. we have not formally determined binding constants,
these data suggest that the Kd for 9- and 13-HODE bind-
ing is likely to be in the 10±20 mM range, approximately9-HODE and 13-HODE Are Ligands of PPARg
an order of magnitude higher than 15d-PGJ2. This is inNext, we investigated whether oxidized linoleic acid me-
tabolites could bind directly to PPARg. To explore this good agreement with the effective concentration of
Cell
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Figure 6. 9-HODE and 13-HODE Are PPARg Ligands
Figure 5. 9-HODE and 13-HODE Induce Expression of CD14 and Ligand displacement assays were performed using a baculovirus-
CD36 on Monocytic Cells expressed mPPARg1-GST fusion protein immobilized on glutathi-
one-Sepharose beads and [3H]-BRL49653. The data are presentedHuman peripheral monocytes (A) or THP-1 cells (B and C) were
treated with the indicated combinations of 15 mg/ml 9-HODE or 13- as percent specific binding of [3H]-BRL49653 in the absence of a
competitor. Specific binding was defined as the total counts lessHODE and 100 nM LG268 for 4 days. CD14 or CD36 expression
levels were determined by flow cytometry. Mean fluorescence inten- nonspecific binding to the glutathione Sepharose-GST/PPARg ma-
trix. Nonspecific binding (less than 10% of total counts) was definedsities (A and B) and fluorescence distribution (C) of the counted
populations are presented. Each experiment was repeated at least as residual binding in the presence of 100-fold excess of cold
BRL49653. Each experimentwas performed at least three times withthree times with similar results.
similar results. (A) 15d-PGJ2 and oxidized linoleic acid metabolites
compete for [3H]-BRL49653 binding to PPARg. 15d-PGJ2 and
BRL49653 wereadded at a final concentration of 10 mM andoxidized
these compounds in transient transfection assays (Fig- fatty acids at 100 mM. (B) Dose-response competition curves for
9-HODE and 13-HODE binding to PPARg.ure 4). The oxo metabolites of linoleic acid showed some-
what higher affinity binding to PPARg (13-oxoODE .
9-oxoODE . 9-HODE . 13-HODE), consistent with their
into the cell, (3) selective lipid uptake from membrane-potency as transcriptional activators (data not shown).
bound oxLDL particles, and (4) intracellular release of
ligand following endocytosis of the particle.
To determine whether free ligand was diffusing fromActivation of PPARg by OxLDL Involves Scavenger
Receptor-Mediated Cellular Uptake the oxLDL particle over time, we passed the oxLDL
preparation through a filter with a molecular weight cut-The above observations strongly suggest that the ability
of oxLDL to activate PPARg-dependent transcription off of 10,000 and examined the ability this material to
activate PPARg-dependent transcription. No PPARg ac-stems from its ability to provide the cell with oxidized
linoleic acid ligands of PPARg. Since this represents a tivation was observed with the ,10 kDa fraction while
the .10 kDa fraction yielded an activation profile identi-novel pathway for activation of a nuclear receptor, we
endeavored to characterize in detail the molecular mech- cal to that of unfiltered oxLDL (data not shown). This
finding indicates that the PPARg ligand is confined toanisms involved in the delivery of PPARg ligand from
the oxLDL particle to the nucleus. Theoretically, four the oxLDL particle and is not passively released into
aqueous solution.different mechanisms of PPARg activation are possible:
(1) passive diffusion of ligand from the particle into the Early in the course of this work, it was noted that
oxLDL could activate PPAR-dependent transcription incell, (2) facilitated transport of extracellular free ligand
Components of Oxidized LDL Are PPARg Ligands
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Figure 7. Activation of PPARg by OxLDL Involves Scavenger Receptor-Mediated Cellular Uptake
(A) Activation of PPARg in HeLa and CV-1 cells by LDL, oxLDL, or 9-HODE. Cells were transfected as described in Figure 3 and treated with
100 mg protein/ml LDL, oxLDL, or 20 mg/ml 9-HODE. Normalized reporter activity was determined, and the means of three independent
determinations 6 SD are shown.
(B) Association of DiI-LDL and DiI-oxLDL to CV-1 and HeLa cells. Cells were incubated in the presence of fluorescent-labeled lipoprotein and
cell-associated fluorescence was determined by flow cytometry. Mean fluorescence intensities are presented.
(C) Cellular uptake of DiI-labeled LDL (i and ii) and oxLDL (iii and iv) by HeLa and CV-1 cells. Cells were incubated in the presence of 50 mg/
ml DiI-labeled LDL or oxLDL and internalized label was visualized by fluorescence microscopy.
(D) Ectopic expression of the scavenger receptor CD36 facilitates activation of PPARg-dependent transcription by oxLDL. CV-1 cells were
transfected with the Gal-mPPARg-LBD based reporter system in the presence or absence of an expression vector for mCD36 and 50 mg
protein/ml oxLDL. Normalized luciferase activity and fold induction were determined, and the means of three independent determinations 6
SD are shown.
CV-1 cells, but not in HeLacells (Figure7A). One possible with CV-1 and HeLa cells. Figures 7B and 7C demon-
strate that while LDL associates with both cell lines,explanation for this phenomenon was that CV-1 cells
but not HeLa cells expressed a selective transporter oxLDL associates only with CV-1 cells. This association
is saturable (Figure 7B) and can be competed with ex-that facilitated uptake of free PPARg ligand. This possi-
bility was excluded by the observation that free 9-HODE cess unlabeled oxLDL (data not shown), indicating that it
is receptor-mediated. Several conclusionscan be drawnand thiazolidinedione ligands can activate PPARg in both
CV-1 and HeLa cells (Figure 7A and data not shown). from these studies. First, the differential ability of native
LDL and oxLDL toactivate PPARg does not reflect differ-An alternative possibility was that CV-1 and HeLa cells
differed in their ability to bind and/or internalize the ential association of these particles with CV-1 cells. Both
associate, but only oxLDL activates. Second, cell asso-oxLDL particle itself. As a first step in addressing this
possibility, we compared cell association (a combina- ciation of the oxLDL particle is apparently required for
activation of PPARg. Last, the kinetics of oxLDL bindingtion of binding and uptake) of DiI-LDL and DiI-oxLDL
Cell
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to CV-1 cells is consistent with a scavenger receptor- Discussion
mediated process (Endemann et al., 1993) and corre-
lates well with the concentration of oxLDL (10±50 mg/ Oxidized LDL has been hypothesized toplay a causative
ml) needed for activation of PPARg-dependent tran- role in atherosclerotic plaque formation (reviewed in
scription (Figures 3A and 3C). Steinberg, 1997). Oxidative modification of cholesterol,
Next, we examined whether the mechanism of PPARg fatty acid, and protein components of LDL results in the
activation by oxLDL involves internalization of the entire formation of a lipoprotein particle with distinct biologic
particle or the selective uptake of lipid from a receptor- activities. We have shown here that oxLDL activates
bound particle. For example, cellular uptake of choles- PPARg-dependent transcription through a novel signal-
terol from LDL involves receptor-mediated endocytosis ing mechanism involving scavenger receptor-mediated
of the particle (Goldstein and Brown, 1977), while cho- cellular uptake. A screen of lipid components of the
lesterol uptake from HDL particles by the HDL receptor oxLDL particle identified two oxidized metabolites of
SR-BI occurs by selective lipid uptake (Acton et al., linoleic acid (9-HODE and 13-HODE) that were able to
1996). Krieger and associates have shown that these bind and activate PPARg. These findings suggest that
two uptake mechanisms result in dramatically different 9- and 13- HODE may function as pathologic endoge-
cellular distributions of the fluorescent lipid DiI (Acton nous ligands for PPARg and play a direct role in the
et al., 1996). The fluorescence micrograph shown in Fig- regulation of macrophage gene expression during ath-
ure 7C compares the ability of HeLa and CV-1 cells to erogenesis.
internalize fluorescent label (DiI) following exposure to Exposure of monocytes and macrophages to oxidized
DiI-labeled LDL or oxLDL. Both lines readily internalized LDL has a range of biological consequences, including
LDL (panels i and ii); however, only CV-1 cells internal- enhanced monocyte maturation, increased adhesive
ized oxLDL (compare panels iii and iv). Careful examina- properties, expression of scavenger receptors, and pro-
tion reveals that internalization of DiI from either LDL duction of cytokines and growth factors (Lehr et al.,
or oxLDL resulted in a punctate fluorescence pattern 1993; Thomas et al., 1994; Hamilton et al., 1995; Lipton
characteristic of receptor-mediated endocytosis to en- et al., 1995; Han et al., 1997). These diverse effects are
dosomes and lysosomes (Figure 7C, ii and iv insets). collectively thought to contribute to atherogenesis. As
In order to obtain direct evidence for intracellular pro- one might expect, the influence of oxLDL on macro-
cessing of the apolipoprotein component of the particle,
phage gene expression is complex and context-depen-
CV-1 and HeLa cells were incubated in the presence of
dent. Exposure of resting macrophages to oxLDL leads125I-labeled native and oxLDL. Intracellular degradation
to increased expression of CD11b, CD18 (Lehr et al.,
was assayed by determining the radioactivity of the
1993), the scavenger receptors SR-A and CD36 (Han et
acid-soluble material in the culture medium (Goldstein
al., 1997; this work), and cytokines such IL-1a and IL-
and Brown, 1977). Both cell lines readily metabolized
1b (Thomas et al., 1994; Lipton et al., 1995). At the samelabeled native LDL (data not shown). However, in the
time, oxLDL has been reported to suppress the INFg-case of labeled oxLDL, the medium of CV-1 cells (3495
or LPS-induced expression of TNFa, IP-10, and IL-1bcpm/plate) but not HeLa cells (1159 cpm/plate) con-
(Fong et al., 1991; Hamilton et al., 1995; Ohlsson et al.,tained increased levels of acid-soluble radioactivity com-
1996). Interestingly, two groups have recently reportedpared to the control (no cell) plates (1130 cpm/plate).
that PPARg ligands can also function to suppress cyto-Thus, the oxLDL particle is internalized and processed
kine production in activated macrophages (Jiang et al.,by CV-1 cells.
1998; Ricote etal., 1998). Thus, the effects of both oxLDLAs a final test of this model, we investigated whether
and PPARg ligands on macrophage gene expressionoverexpression of the scavenger receptor CD36 could
are dependent on the activation state of the cell. Thesefacilitate activation of PPARg by oxLDL. CD36 was origi-
context-dependent effects may help to explain whynally identified as an oxLDL receptor by virtue of its
oxLDL-exposed macrophages maintain a chronic ratherability to endow transfected cells with the capacity to
than fulminant inflammatory reaction at sites of athero-take up oxLDL (Endemann et al., 1993). Transient trans-
sclerosis.fections of CV-1 cells were performed as above, and
While the mechanisms that transduce signals fromthe ability of oxLDL to activate PPARg-dependent tran-
oxLDL to the nucleus are not well defined, previousscription was examined in the presence or absence of
studies have suggested that isolated protein and lipida cotransfected expression vector for murine CD36. As
components can each recapitulate some of the effectsshown in Figure 7D, cotransfection of the CD36 expres-
of the intact particle. For example, 9-HODE and 13-sion vector strongly enhanced the ability of oxLDL to
HODE have been implicated in the induction of IL-1b (Kufunction as a PPARg activator in these cells. This experi-
et al., 1992). Interestingly, the concentrations of thesement provides direct evidence that expression of the
compounds needed to induce CD14 and CD36 in ourcell surface oxLDL receptor CD36 is coupled to tran-
assays are identical to those reported by Ku et al. forscriptional activation by PPARg. Together with the data
IL-1b. Our identification of these compounds as activa-presented above, this result strongly suggests that scav-
tors of PPARg provides a novel mechanism to explainenger receptor-mediated internalization of the oxLDL
at least some of the biologic effects of oxLDL. It isparticle is required for activation of PPARg. Furthermore,
important to note, however, that oxLDL also possessessince free 9-HODE cholesteryl ester (the predominant
activities that are not shared with PPARg ligands, suchform of 9-HODE in the oxLDL particle) cannot activate
as the ability to induce SR-Aexpression (Figure2). ThesePPARg-dependent transcription, it is likely that intracel-
effects may be mediated by surface receptor-linked sig-lular processing of the particle and cleavage of the ester
bond are required for the liberation of PPARg ligand. naling pathways (Huang et al., 1991).
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et al., 1990). Given the tremendous amount of oxidized
LDL accumulated by foam cells in vivo, the intracellular
concentration of 9- and 13-HODE within foam cells in
vivo is very likely to exceed the concentration required
for activation of PPARg.
Cell surface receptor-mediated endocytosis of a lipo-
protein particle represents a previously unrecognized
mechanism of ligand delivery to a nuclear receptor. Un-
like other nuclear receptor activators such as steroid
hormones, which gain easy access to the nucleus be-
cause of their lipid solubility, oxLDL is apparently able
to activate PPARg-dependent transcription only in cells
that can bind and internalize the oxLDLparticle via scav-
enger receptors. In this novel pathway, signaling through
a surface receptor is directly coupled to signaling throughFigure 8. ANovel Metacrine Signaling Pathway Coupling Scavenger
a nuclear receptor. The majority of the PPARg bindingReceptor-Mediated OxLDL Uptake to Activation of PPARg
components of oxLDL, 9-, and 13-HODE, are present
in the form of cholesteryl esters. Since free 9-HODE
PPARg was originally identified as an orphan nuclear cholesteryl ester was inactive in transient transfection
receptor and an adipocyte transcription factor (Kliewer experiments, we speculate that both scavenger recep-
et al., 1992; Tontonoz et al., 1994a). It has been rescued tor±mediated uptake and lysosomal hydrolysis are likely
from the orphanage by the identification of naturally to be indispensable for the generation of ligand from
occurring (15d-PGJ2) and synthetic (thiazolidinedione) the oxLDL particle. An intriguing possibility is that li-
ligands (Forman et al., 1995; Kliewer et al., 1995; Leh- gands for othernuclear receptors mayalso be generated
mann et al., 1995). Recently, it has been demonstrated from lipoprotein particles by similar mechanisms.
that certain members of the PPAR family (a and d) can The lipoprotein metabolism of macrophages is funda-
recognize a broad array of polyunsaturated fatty acids, mentally different from that of other cells. Macrophages
including linoleic and arachidonic acid (Forman et al., internalize modified LDL through scavenger receptors,
1997; Kliewer et al., 1997). In the case of PPARg, while which unlike LDL receptors, are not down-regulated by
some labs have found polyunsaturated fatty acids such high intracellular cholesterol levels (for a review, see
as linoleic acid to be activators at high concentrations Brown and Goldstein, 1983). On the contrary, exposure
(Kliewer et al., 1997), we have reported that these fatty to higher oxLDL levels results in increased receptor ex-
acids are relatively poor activators of PPARg compared pression. As a result, macrophages incubated continu-
to the other PPARs (Forman et al., 1997). In the present ously with oxLDL are converted into foam cells. This
work, we have shown that oxidative modification of lino- phenomenon implies the existence of a mechanism
leic acid results in the formationof more effectivePPARg whereby the scavenger receptor substrate (i.e., oxLDL)
activators. While this finding has important implications initiates and promotes its own uptake by increasing the
for PPARg signaling in macrophages, it remains to be level of receptor expression. Collectively, the data pre-
determined whether activation by oxidized fatty acids sented in this work and in the accompanying paper
plays a significant role in PPARg-mediated processes (Tontonoz et al., 1998) implicate the PPARg:RXR hetero-
in other tissues. Interestingly, oxLDL, like other PPARg dimer in a signaling pathway that couples cellular uptake
activators, can promote the differentiation of cultured of oxLDL with transcriptional activation of the scavenger
adipocyte cell lines (our unpublished data). receptor CD36 by PPARg (Figure 8). Oxidative modifica-
There is considerable evidence to support a role for tion of the LDL particle endows it with the ability to bind
oxidized fatty acids as important signaling molecules in scavenger receptors and at the same time converts a
the context of the athersclerotic lesion. Oxidized lipids, component of the particle, linoleic acid, into an effective
including oxidized fatty acids, were detected in athero- activator of PPARg (9-HODE, 13-HODE). Thus, as a con-
sclerotic lesions in the early 1950s (Glavind et al., 1952; sequence of oxLDL internalization by receptor-medi-
Yla-Herttuala et al., 1989). 9- and 13-HODE in particular ated endocytosis, an activating signal for PPARg is for-
are present at high levels in advanced lesions. It has warded to the nucleus. Transcriptional activation of
been estimated that fibrous plaques contain 89 mg oxi- PPARg initiates a positive feedback loop that enhances
dized fatty acid/g lipid (total sterol esters) and ulcerated the expression of the oxLDL receptor CD36. This attrac-
plaques 335 mg/g lipid (Harland et al., 1971). It has also tive metacrine regulatory circuit suggests a novel mech-
been shown that the amount of 9- and 13- HODE in anism whereby oxLDL and its component lipids may
human atherosclerotic lesions correlates directly with contribute to foam cell formation and the regulation of
the severity of the lesion (Harland et al., 1971). Since macrophage gene expression during atherogenesis.
the work presented here has utilized oxLDL prepared
in vitro, it is important to note that the lipid profile gener-
Experimental Proceduresated by CuSO4-mediated oxidation is very similar to the
profile of oxLDL in vivo (Lenz et al., 1990; Thomas and
Materials
Jackson, 1991). One biochemical analysis of in vitro Chemicals were purchased from Sigma, unless otherwise indicated.
oxidized LDL found that 67% of the oxidized linoleate LDL, oxidized LDL (Steinbrecher et al., 1984), and DiI- or 125I-labeled
lipoproteins were purchased from Perimmune. OxLDL preps wereproducts were present as 9- and 13- derivatives (Lenz
Cell
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filtrated through a Microcon 10 filter (Amicon). Fatty acids, oxidized pPPAREx3-TK-luc, pCMX-b-galactosidase, and nuclear or scaven-
ger receptor expression vectors (as indicated in the text and thefatty acids, and prostanoids were from Cayman. The RXR-selective
ligand LG268 and [3H]-BRL49653 were kind gifts of Dr. R. Heyman, figure legends) were transfected by liposomal delivery (DOTAP,
Boehringer Mannheim) according to manufacturer's directions.Ligand Pharmaceuticals. The monoclonal antibodies used in this
study were: R-phycoerythrin (RPE)-conjugated anti-human CD14 When necessary, a carrier plasmid (pGEM4) was added to ensure
equal DNA amounts in each transfection. After 16 hr of transfection,(clone TUK4, DAKO), fluorescein isothiocyanate (FITC)-conjugated
anti-human CD18 (clone MHM23, DAKO), and FITC-conjugated anti- medium was changed and ligand or lipoproteins were added as
indicated. Cells were harvested after 24 additional hr of growth, andmouse and anti-rabbit immunoglobulins (DAKO). Anti-human CD36
(clone 8A6) mouse monoclonal antibody was a kind gift of Dr. J. luciferase activity was determined and normalized to the b-galac-
tosidase activity. Each transfection was carried out in triplicate andBarnwell (NYU), and anti-human SR-AI/II was a kind gift of Dr.
C. K. Glass (UCSD). Expression vectors for mouse and human repeated at least three times.
PPARg ( pCMX-mPPARg), hRXRa ( pCMX-RXRa), Gal4-DBD fusion
of mPPARg-LBD (pCMX-Gal-mPPARg-LBD), and hRXRa-LBD ( pCMX- Ligand Binding Assays
hRXRa-LBD) reporter genes pMH-100-TK-luc or pPPAREx3-TK-luc Ligand binding assays were performed using a baculovirus-
and pCMXb-gal were described previously (Forman et al., 1995). expressed mPPARg1-GST fusion protein. SF9 cell pellets were
lysed in 400 mM KCl, 20 mM TRIS (pH 8.0), 1 mM ETDA, 1 mM
Cell Culture and RNA Analysis DTT, and 0.1% Triton X-100, and the fusion protein purified by
THP-1, HeLa, and CV-1 cells were obtained from ATCC and cultured glutathione-Sepahrose affinity chromatography. The fusion protein-
in RPMI 1640 medium (THP-1) or in DMEM (293, HeLa, CV-1) in the bound beads were used directly in a binding reaction with 100 nM
presence of 10% FCS (Summit). THP-1 cells and human monocytes [3H]-BRL49653 (31 Ci/mmol) in a buffer containing 10 mM Tris (pH
were treated with the indicated amount of lipoproteins or synthetic 8.0), 50 mM KCl, and 10 mM DTT. Competitor ligands or solvent
compounds for 4 days unless otherwise indicated. Human periph- carrier (ethanol) were added as indicated. Following incubation for
eral blood from healthy volunteers was collected in 10 mM sodium 2 hr at 48C, the PPARg-Sepharose beads were isolated by centrifu-
citrate. Erythrocytes and neutrophils were removed by low-speed gation, washed with 10 vol of binding buffer, and the bound counts
centrifugation in Vacutainer CPT cell preparation tubes (Beckton- determined by liquid scintillation counting. Each experiment was
Dickinson) according to manufacturer's instructions. Cells were cul- repeated three times with similar results.
tured in RPMI 1640 with 10% autologous serum overnight, and
nonadherent platelets and other cells were removed by washing.
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